JP2023545684A - ポリペプチドコンジュゲートおよび使用の方法 - Google Patents
ポリペプチドコンジュゲートおよび使用の方法 Download PDFInfo
- Publication number
- JP2023545684A JP2023545684A JP2023520019A JP2023520019A JP2023545684A JP 2023545684 A JP2023545684 A JP 2023545684A JP 2023520019 A JP2023520019 A JP 2023520019A JP 2023520019 A JP2023520019 A JP 2023520019A JP 2023545684 A JP2023545684 A JP 2023545684A
- Authority
- JP
- Japan
- Prior art keywords
- seq
- repeat
- polypeptide conjugate
- sequence
- polypeptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/70—Vectors or expression systems specially adapted for E. coli
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Endocrinology (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Toxicology (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Immunology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2020119335 | 2020-09-30 | ||
| CNPCT/CN2020/119335 | 2020-09-30 | ||
| CN2021099030 | 2021-06-09 | ||
| CNPCT/CN2021/099030 | 2021-06-09 | ||
| PCT/CN2021/122075 WO2022068920A1 (en) | 2020-09-30 | 2021-09-30 | Polypeptide conjugates and methods of uses |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023545684A true JP2023545684A (ja) | 2023-10-31 |
| JP2023545684A5 JP2023545684A5 (cg-RX-API-DMAC7.html) | 2024-10-08 |
Family
ID=80951233
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023520019A Pending JP2023545684A (ja) | 2020-09-30 | 2021-09-30 | ポリペプチドコンジュゲートおよび使用の方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US11529394B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4222176A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2023545684A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20230083294A (cg-RX-API-DMAC7.html) |
| CN (3) | CN115925995A (cg-RX-API-DMAC7.html) |
| CA (1) | CA3193453A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022068920A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3193453A1 (en) * | 2020-09-30 | 2022-04-07 | Beijing Ql Biopharmaceutical Co., Ltd. | Polypeptide conjugates and methods of uses |
| KR20240118914A (ko) | 2021-01-20 | 2024-08-05 | 바이킹 테라퓨틱스 인코포레이티드 | 대사 및 간 질환 치료를 위한 조성물 및 방법 |
| CA3231953A1 (en) | 2021-09-15 | 2023-03-23 | Brian Lian | Compositions and methods for the treatment of metabolic and liver disorders |
| WO2023179796A1 (en) * | 2022-03-25 | 2023-09-28 | Beijing Ql Biopharmaceutical Co., Ltd. | Pharmaceutical compositions of polypeptide conjugates and methods of uses thereof |
| WO2023186003A1 (en) * | 2022-03-30 | 2023-10-05 | Beijing Ql Biopharmaceutical Co., Ltd. | Liquid pharmaceutical compositions of polypeptide conjugates and methods of uses thereof |
| EP4323413A4 (en) * | 2022-03-30 | 2025-10-15 | Beijing Ql Biopharmaceutical Co Ltd | LIQUID PHARMACEUTICAL COMPOSITIONS OF POLYPEPTIDE CONJUGATES AND METHODS OF USE THEREOF |
| WO2025185605A1 (en) * | 2024-03-05 | 2025-09-12 | Beijing Ql Biopharmaceutical Co., Ltd. | Polypeptide conjugates and methods of uses |
| WO2026008836A1 (en) * | 2024-07-05 | 2026-01-08 | Novo Nordisk A/S | Glp-1 derivatives and uses thereof |
| WO2026092580A1 (en) | 2024-10-30 | 2026-05-07 | Ascletis Pharma (China) Co., Limited | Glp-1r\gipr\gcgr modulator in combination with thr-beta modulator for treatment of metabolic diseases |
| WO2026092581A1 (en) | 2024-10-30 | 2026-05-07 | Ascletis Pharma (China) Co., Limited | Thyroid hormone receptor beta modulator alone or in combination with a modulator of glp-1r, gipr or gcgr, for use in the treatment of obesity or overweight or for treating alopecia areata |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2000500505A (ja) * | 1996-08-30 | 2000-01-18 | ノボ ノルディスク アクティーゼルスカブ | Glp―1誘導体 |
| JP2004528014A (ja) * | 2000-12-07 | 2004-09-16 | イーライ・リリー・アンド・カンパニー | Glp−1融合タンパク質 |
| JP2007505840A (ja) * | 2003-09-19 | 2007-03-15 | ノボ ノルディスク アクティーゼルスカブ | 新規glp−1誘導体 |
| JP2008533105A (ja) * | 2005-03-18 | 2008-08-21 | ノボ ノルディスク アクティーゼルスカブ | アシル化glp−1化合物 |
| JP2013144684A (ja) * | 2009-12-16 | 2013-07-25 | Novo Nordisk As | 二重アシル化glp−1誘導体 |
| JP2017507124A (ja) * | 2015-01-09 | 2017-03-16 | イーライ リリー アンド カンパニー | Gipおよびglp−1コアゴニスト化合物 |
| JP2019504106A (ja) * | 2015-10-28 | 2019-02-14 | タフツ ユニバーシティー | タンパク質分解安定性が改善された新規ポリペプチド並びにその調製方法及び使用方法 |
Family Cites Families (80)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
| ES2113879T3 (es) | 1990-01-24 | 1998-05-16 | Douglas I Buckley | Analogos de glp-1 utiles para el tratamiento de diabetes. |
| US5869602A (en) | 1995-03-17 | 1999-02-09 | Novo Nordisk A/S | Peptide derivatives |
| US6268343B1 (en) | 1996-08-30 | 2001-07-31 | Novo Nordisk A/S | Derivatives of GLP-1 analogs |
| US7235627B2 (en) | 1996-08-30 | 2007-06-26 | Novo Nordisk A/S | Derivatives of GLP-1 analogs |
| US6458924B2 (en) | 1996-08-30 | 2002-10-01 | Novo Nordisk A/S | Derivatives of GLP-1 analogs |
| UA65549C2 (uk) | 1996-11-05 | 2004-04-15 | Елі Ліллі Енд Компані | Спосіб регулювання ожиріння шляхом периферійного введення аналогів та похідних glp-1 (варіанти) та фармацевтична композиція |
| EP2319854B1 (en) | 1997-01-08 | 2016-11-30 | Sigma-Aldrich Co. LLC | Bioconjugation Of Macromolecules |
| AU3247799A (en) | 1998-02-27 | 1999-09-15 | Novo Nordisk A/S | Glp-1 derivatives of glp-1 and exendin with protracted profile of action |
| EP1060191B1 (en) | 1998-02-27 | 2010-04-28 | Novo Nordisk A/S | Derivatives of glp-1 analogs |
| DE69916811T2 (de) | 1998-02-27 | 2005-04-14 | Novo Nordisk A/S | Glp-1 derivate mit einem helix-gehalt über 25 %, die partiell strukturierte mizellenartige aggregate bilden |
| JP2002508162A (ja) | 1998-02-27 | 2002-03-19 | ノボ ノルディスク アクティーゼルスカブ | N末端を短縮したglp−1誘導体 |
| AU2610899A (en) | 1998-02-27 | 1999-09-15 | Novo Nordisk A/S | N-terminally modified glp-1 derivatives |
| AU5027299A (en) | 1998-07-31 | 2000-02-28 | Novo Nordisk A/S | Use of glp-1 and analogues for preventing type ii diabetes |
| US6444788B1 (en) | 1999-03-15 | 2002-09-03 | Novo Nordisk A/S | Ion exchange chromatography of GLP-1, analogs and derivatives thereof |
| WO2001053480A1 (en) * | 2000-01-24 | 2001-07-26 | Sangamo Biosciences, Inc. | Nucleic acid binding polypeptides characterized by flexible linkers connected nucleic acid binding modules |
| ES2464532T3 (es) | 2001-04-19 | 2014-06-03 | The Scripps Research Institute | Métodos y composiciones para la producción de pares ortogonales de ARNt-aminoacil-ARNt sintetasa |
| US6441163B1 (en) | 2001-05-31 | 2002-08-27 | Immunogen, Inc. | Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents |
| JP5275566B2 (ja) | 2003-06-18 | 2013-08-28 | ザ スクリプス リサーチ インスティチュート | 反応性非天然アミノ酸遺伝コード付加 |
| CN100444898C (zh) | 2003-09-19 | 2008-12-24 | 诺沃挪第克公司 | 治疗肽的清蛋白结合型衍生物 |
| ES2605443T3 (es) | 2003-11-06 | 2017-03-14 | Seattle Genetics, Inc. | Conjugados de auristatina con anticuerpos anti-HER2 o anti-CD22 y su uso en terapia |
| JP2007537141A (ja) | 2003-12-18 | 2007-12-20 | ノボ ノルディスク アクティーゼルスカブ | 新規なglp−1化合物 |
| CN101665538A (zh) | 2003-12-18 | 2010-03-10 | 诺沃挪第克公司 | 与白蛋白样物质相连的新glp-1类似物 |
| EP1771205B1 (en) | 2004-06-18 | 2016-10-26 | Ambrx, Inc. | Novel antigen-binding polypeptides and their uses |
| TR201808537T4 (tr) | 2004-09-23 | 2018-07-23 | Genentech Inc | Sistein değiştirilmiş antikorlar ve konjugatlar. |
| JP2008515856A (ja) | 2004-10-07 | 2008-05-15 | ノボ ノルディスク アクティーゼルスカブ | 遅延性glp−1化合物 |
| ES2484796T3 (es) | 2005-03-18 | 2014-08-12 | Novo Nordisk A/S | Compuestos de GLP-1 extendidos |
| ATE507235T1 (de) | 2006-02-08 | 2011-05-15 | Lonza Ag | Synthese von glucagon-ähnlichen peptiden |
| CA2644712C (en) | 2006-03-06 | 2016-09-13 | Amunix, Inc. | Unstructured recombinant polymers and uses thereof |
| CA2653748A1 (en) | 2006-05-02 | 2007-11-15 | Allozyne, Inc. | Non-natural amino acid substituted polypeptides |
| US8563521B2 (en) | 2007-06-21 | 2013-10-22 | Technische Universitat Munchen | Biological active proteins having increased in vivo and/or in vitro stability |
| CA2695374A1 (en) | 2007-08-15 | 2009-02-19 | Amunix, Inc. | Compositions and methods for modifying properties of biologically active polypeptides |
| EP2190872B1 (en) | 2007-09-05 | 2018-03-14 | Novo Nordisk A/S | Glucagon-like peptide-1 derivatives and their pharmaceutical use |
| US20100261637A1 (en) | 2007-09-05 | 2010-10-14 | Novo Nordisk A/S | Peptides derivatized with a-b-c-d- and their therapeutical use |
| US20100292133A1 (en) | 2007-09-05 | 2010-11-18 | Novo Nordisk A/S | Truncated glp-1 derivaties and their therapeutical use |
| US20100317057A1 (en) | 2007-12-28 | 2010-12-16 | Novo Nordisk A/S | Semi-recombinant preparation of glp-1 analogues |
| CN102149411A (zh) | 2008-09-12 | 2011-08-10 | 诺沃—诺迪斯克有限公司 | 酰化肽或蛋白的方法 |
| DK3178835T3 (da) | 2009-02-03 | 2019-06-24 | Amunix Pharmaceuticals Inc | Forlængede rekombinante polypeptider og sammensætninger omfattende samme |
| WO2010144508A1 (en) | 2009-06-08 | 2010-12-16 | Amunix Operating Inc. | Glucose-regulating polypeptides and methods of making and using same |
| US20110312881A1 (en) | 2009-12-21 | 2011-12-22 | Amunix, Inc. | Bifunctional polypeptide compositions and methods for treatment of metabolic and cardiovascular diseases |
| EP4450523A3 (en) | 2010-04-02 | 2025-03-12 | Amunix Pharmaceuticals, Inc. | Binding fusion proteins, binding fusion protein-drug conjugates, xten-drug conjugates and methods of making and using same |
| CN103003300B (zh) * | 2010-04-27 | 2017-06-09 | 西兰制药公司 | Glp‑1受体激动剂和胃泌素的肽缀合物及其用途 |
| TW201203798A (en) | 2010-07-01 | 2012-01-16 | Tricore Corp | Tray sealant filling fixture for spindle motor and the sealant filling method |
| JP6231386B2 (ja) | 2010-11-09 | 2017-11-15 | ノヴォ ノルディスク アー/エス | リンカーを有する二重アシル化されたglp−1誘導体 |
| AU2012241894B2 (en) * | 2011-04-12 | 2015-12-03 | Novo Nordisk A/S | Double-acylated GLP-1 derivatives |
| CN102786590A (zh) * | 2011-05-19 | 2012-11-21 | 江苏豪森药业股份有限公司 | 分枝型peg修饰的glp-1类似物及其可药用盐 |
| JP6126097B2 (ja) | 2011-09-06 | 2017-05-10 | ノヴォ ノルディスク アー/エス | Glp−1誘導体 |
| ES2687651T3 (es) | 2011-09-12 | 2018-10-26 | Amunix Operating Inc. | Composiciones de péptido-2 similar a glucagón y métodos para producir y usar los mismos |
| CN111548418A (zh) | 2012-02-15 | 2020-08-18 | 比奥贝拉蒂治疗公司 | 因子viii组合物及其制备和使用方法 |
| CN104302408B (zh) | 2012-02-27 | 2016-12-14 | 阿穆尼克斯运营公司 | Xten缀合组合物和制造其的方法 |
| JP6254146B2 (ja) | 2012-03-27 | 2017-12-27 | エヌジーエム バイオファーマシューティカルス,インコーポレーテッド | 代謝障害を治療するための組成物および方法 |
| EP2846823B1 (en) | 2012-05-08 | 2019-12-04 | Novo Nordisk A/S | Double-acylated glp-1 derivatives |
| CN104411322B (zh) * | 2012-05-08 | 2017-05-24 | 诺和诺德股份有限公司 | 双酰化glp‑1衍生物 |
| CN107320719A (zh) | 2012-06-05 | 2017-11-07 | 阿穆尼克斯运营公司 | Hgh‑xten融合蛋白及其在治疗生长激素缺乏中的用途 |
| ES2770501T3 (es) | 2012-07-11 | 2020-07-01 | Bioverativ Therapeutics Inc | Complejo del factor VIII con XTEN y proteína del factor de Von Willebrand y sus usos |
| WO2014060472A1 (en) | 2012-10-17 | 2014-04-24 | Novo Nordisk A/S | Fatty acid acylated amino acids for oral peptide delivery |
| WO2014164568A1 (en) | 2013-03-11 | 2014-10-09 | Amunix Operating Inc. | Treatment of pediatric growth hormone deficiency with human growth hormone analogues |
| AU2014283221A1 (en) | 2013-06-20 | 2015-12-03 | Novo Nordisk A/S | GLP-1 derivatives and uses thereof |
| JP6139712B2 (ja) | 2013-07-04 | 2017-05-31 | ノヴォ ノルディスク アー/エス | Glp−1様ペプチドの誘導体及びその使用 |
| US10548953B2 (en) | 2013-08-14 | 2020-02-04 | Bioverativ Therapeutics Inc. | Factor VIII-XTEN fusions and uses thereof |
| CN105451776B (zh) * | 2013-08-15 | 2020-04-17 | 诺和诺德股份有限公司 | Glp-1衍生物及其用途 |
| WO2015155151A1 (en) | 2014-04-07 | 2015-10-15 | Novo Nordisk A/S | Double-acylated glp-1 compounds |
| WO2016077505A2 (en) | 2014-11-11 | 2016-05-19 | Amunix Operating Inc. | Targeted xten conjugate compositions and methods of making same |
| JP6730278B2 (ja) | 2014-11-27 | 2020-07-29 | ノヴォ ノルディスク アー/エス | Glp−1誘導体及びその使用 |
| EP3233898A1 (en) | 2014-12-17 | 2017-10-25 | Novo Nordisk A/S | Glp-1 derivatives and uses thereof |
| WO2016131893A1 (en) * | 2015-02-18 | 2016-08-25 | Medimmune Limited | Incretin fusion polypeptides |
| EP3303380B1 (en) * | 2015-06-02 | 2020-01-15 | Novo Nordisk A/S | Insulins with polar recombinant extensions |
| IL319047A (en) | 2015-08-28 | 2025-04-01 | Amunix Operating Inc | Chimeric polypeptide composition and methods for its preparation and use |
| JP6712323B2 (ja) | 2015-12-31 | 2020-06-17 | ハンミ ファーマシューティカル カンパニー リミテッド | グルカゴン、glp−1及びgip受容体のすべてに活性を有する三重活性体 |
| AR107560A1 (es) | 2016-02-24 | 2018-05-09 | Lilly Co Eli | Compuesto que disminuye la glucosa en la sangre |
| WO2017149070A1 (en) | 2016-03-03 | 2017-09-08 | Novo Nordisk A/S | Glp-1 derivatives and uses thereof |
| WO2017210100A1 (en) * | 2016-06-02 | 2017-12-07 | Indiana University Research And Technology Corporation | Glucagon-like peptide-1-t3 conjugates |
| TWI710377B (zh) | 2017-05-23 | 2020-11-21 | 丹麥商諾佛 儂迪克股份有限公司 | Mic-1化合物及其用途 |
| CN110945017B (zh) | 2017-07-19 | 2024-07-16 | 诺和诺德股份有限公司 | 双功能化合物 |
| CN115814063B (zh) * | 2018-04-19 | 2026-07-28 | 杭州先为达生物科技股份有限公司 | Glp-1衍生物及其治疗用途 |
| US11780900B2 (en) * | 2018-04-25 | 2023-10-10 | Janssen Sciences Ireland Unlimited Company | Glucagon like peptide 1 (GLP-1) fusion peptide coupled cyclic peptide tyrosine tyrosine conjugates and uses thereof |
| EP3861017A1 (en) | 2018-10-05 | 2021-08-11 | Novo Nordisk A/S | Bifunctional compounds comprising insulin peptides and egf(a) peptides |
| AU2020256648B2 (en) | 2019-04-11 | 2026-01-15 | Jiangsu Hansoh Pharmaceutical Group Co., Ltd. | Multi-receptor agonist and medical use thereof |
| WO2021136223A1 (en) * | 2019-12-31 | 2021-07-08 | Beijing Ql Biopharmaceutical Co., Ltd. | Fusion proteins of glp-1 and gdf15 and conjugates thereof |
| CA3193453A1 (en) * | 2020-09-30 | 2022-04-07 | Beijing Ql Biopharmaceutical Co., Ltd. | Polypeptide conjugates and methods of uses |
-
2021
- 2021-09-30 CA CA3193453A patent/CA3193453A1/en active Pending
- 2021-09-30 WO PCT/CN2021/122075 patent/WO2022068920A1/en not_active Ceased
- 2021-09-30 JP JP2023520019A patent/JP2023545684A/ja active Pending
- 2021-09-30 KR KR1020237013534A patent/KR20230083294A/ko active Pending
- 2021-09-30 CN CN202211370780.XA patent/CN115925995A/zh active Pending
- 2021-09-30 CN CN202180006277.3A patent/CN114729060B/zh active Active
- 2021-09-30 EP EP21874574.3A patent/EP4222176A4/en active Pending
- 2021-09-30 CN CN202211368599.5A patent/CN115925994B/zh active Active
- 2021-12-27 US US17/562,014 patent/US11529394B2/en active Active
-
2022
- 2022-11-03 US US18/052,215 patent/US20240181016A1/en active Pending
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2000500505A (ja) * | 1996-08-30 | 2000-01-18 | ノボ ノルディスク アクティーゼルスカブ | Glp―1誘導体 |
| JP2004528014A (ja) * | 2000-12-07 | 2004-09-16 | イーライ・リリー・アンド・カンパニー | Glp−1融合タンパク質 |
| JP2007505840A (ja) * | 2003-09-19 | 2007-03-15 | ノボ ノルディスク アクティーゼルスカブ | 新規glp−1誘導体 |
| JP2008533105A (ja) * | 2005-03-18 | 2008-08-21 | ノボ ノルディスク アクティーゼルスカブ | アシル化glp−1化合物 |
| JP2013144684A (ja) * | 2009-12-16 | 2013-07-25 | Novo Nordisk As | 二重アシル化glp−1誘導体 |
| JP2017507124A (ja) * | 2015-01-09 | 2017-03-16 | イーライ リリー アンド カンパニー | Gipおよびglp−1コアゴニスト化合物 |
| JP2019504106A (ja) * | 2015-10-28 | 2019-02-14 | タフツ ユニバーシティー | タンパク質分解安定性が改善された新規ポリペプチド並びにその調製方法及び使用方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| CN115925994B (zh) | 2023-09-22 |
| EP4222176A1 (en) | 2023-08-09 |
| CA3193453A1 (en) | 2022-04-07 |
| CN115925995A (zh) | 2023-04-07 |
| EP4222176A4 (en) | 2024-02-28 |
| US11529394B2 (en) | 2022-12-20 |
| KR20230083294A (ko) | 2023-06-09 |
| CN115925994A (zh) | 2023-04-07 |
| US20220133856A1 (en) | 2022-05-05 |
| WO2022068920A1 (en) | 2022-04-07 |
| US20240181016A1 (en) | 2024-06-06 |
| CN114729060A (zh) | 2022-07-08 |
| CN114729060B (zh) | 2022-11-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11529394B2 (en) | Polypeptide conjugates and methods of uses | |
| US11510990B2 (en) | Conjugates of fusion proteins of GLP-1 and FGF21 | |
| US11453711B2 (en) | Fusion proteins of GLP-1 and GDF15 and conjugates thereof | |
| US12331093B2 (en) | Fusion polypeptides for metabolic disorders | |
| US20250276068A1 (en) | Pharmaceutical compositions of polypeptide conjugates and methods of uses thereof | |
| US20260000770A1 (en) | Liquid pharmaceutical compositions of polypeptide conjugates and methods of uses thereof | |
| WO2023186003A1 (en) | Liquid pharmaceutical compositions of polypeptide conjugates and methods of uses thereof | |
| HK40076645B (en) | Polypeptide conjugates and methods of use | |
| HK40076645A (en) | Polypeptide conjugates and methods of use | |
| HK40099798A (en) | Liquid pharmaceutical compositions of polypeptide conjugates and methods of uses thereof | |
| HK40099798B (en) | Liquid pharmaceutical compositions of polypeptide conjugates and methods of uses thereof | |
| WO2025185605A1 (en) | Polypeptide conjugates and methods of uses |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240927 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20240927 |
|
| RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20250823 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20250916 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20251216 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20260303 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20260703 |